We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 18 for:    hurria

Views and Attitudes of Oncologists and Geriatricians on the Use of Chemotherapy and Hormone Therapy in Treating Older and/or Frail Women With Breast Cancer

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00478283
First Posted: May 24, 2007
Last Update Posted: February 9, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Cancer Institute (NCI)
Information provided by:
City of Hope Medical Center
  Purpose

RATIONALE: A patient's age, health, and ability to perform daily activities may affect which treatment options are offered by doctors to older and/or frail women with breast cancer.

PURPOSE: This clinical trial is studying the views and attitudes of oncologists and geriatricians on the use of chemotherapy and hormone therapy in treating older and/or frail women with breast cancer.


Condition Intervention
Breast Cancer Other: survey administration

Study Type: Interventional
Study Design: Primary Purpose: Health Services Research
Official Title: Perspectives and Attitudes on the Use of Adjuvant Chemotherapy and Hormonal Therapy in Older and/or Frail Women: A Survey of Oncologists and Geriatricians

Resource links provided by NLM:


Further study details as provided by City of Hope Medical Center:

Primary Outcome Measures:
  • Attitudes and perspectives of health professionals
  • Homogeneity of treatment recommendations
  • Relative impact of chronological age, baseline health, and functional status on treatment recommendations

Estimated Enrollment: 300
Study Start Date: December 2006
Study Completion Date: October 2007
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • Evaluate the attitudes and perspectives of 150 oncologists and 150 geriatricians or primary care providers regarding the adjuvant treatment of older women with breast cancer of varying ages, health, and functional status.
  • Determine whether homogeneity exists in treatment recommendations.
  • Determine the relative impact of chronological age, baseline health, and functional status on treatment recommendations.

OUTLINE: Participants complete a 25-minute online survey regarding their treatment recommendations for older women with breast cancer of varying ages, health, and functional status.

PROJECTED ACCRUAL: A total of 300 participants will be accrued for this study.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

DISEASE CHARACTERISTICS:

  • Participants must meet 1 of the following criteria:

    • Oncologist:

      • Must have been in practice ≥ 2 years
      • Must have ≥ 25 postmenopausal breast cancer patients on adjuvant hormonal therapy
      • Cannot work for an advertising agency, market research company, manufacturer or distributor of pharmaceutical products, a pharmacy, drug store, or the FDA
    • Geriatrician:

      • Must have been in practice ≥ 2 years
      • Must be a general practitioner, family practitioner, internal medicine specialist, or geriatrician and received a certificate of added qualification in geriatric medicine and/or treating at least 5 postmenopausal patients who have a history of breast cancer or are currently undergoing treatment for breast cancer
      • Cannot work for an advertising agency, market research company, manufacturer or distributor of pharmaceutical products, a pharmacy, drug store, or the FDA

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00478283


Sponsors and Collaborators
City of Hope Medical Center
National Cancer Institute (NCI)
Investigators
Principal Investigator: Arti Hurria, MD City of Hope Comprehensive Cancer Center
  More Information

Responsible Party: Arti Hurria MD, City of Hope Medical Center
ClinicalTrials.gov Identifier: NCT00478283     History of Changes
Other Study ID Numbers: CDR0000540280
P30CA033572 ( U.S. NIH Grant/Contract )
CHNMC-06187
First Submitted: May 23, 2007
First Posted: May 24, 2007
Last Update Posted: February 9, 2010
Last Verified: February 2010

Keywords provided by City of Hope Medical Center:
breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases